Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for CommercializationPRNewsWire • 09/09/24
Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.GlobeNewsWire • 09/05/24
Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial OfficerGlobeNewsWire • 09/03/24
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/12/24
Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.GlobeNewsWire • 08/07/24
Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United StatesPRNewsWire • 08/07/24
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye DiseaseGlobeNewsWire • 07/30/24
Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye DiseaseGlobeNewsWire • 07/23/24
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and ClobetasolGlobeNewsWire • 05/15/24
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic SuspensionGlobeNewsWire • 04/25/24